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BACKGROUND: The possibility of eradicating cancer by selective destruction of tumour blood vessels may represent an attractive
therapeutic avenue, but most pharmaceutical agents investigated so far did not achieve complete cures and are not completely
specific. Antibody conjugates now allow us to evaluate the impact of selective vascular shutdown on tumour viability and to study
mechanisms of action.
METHODS: We synthesised a novel porphyrin-based photosensitiser suitable for conjugation to antibodies and assessed anticancer
properties of its conjugate with L19, a clinical-stage human monoclonal antibody specific to the alternatively spliced EDB domain of
fibronectin, a marker of tumour angiogenesis.
RESULTS: Here we show in two mouse model of cancer (F9 and A431) that L19 is capable of highly selective in vivo localisation around
tumour blood vessels and that its conjugate with a photosensitiser allows selective disruption of tumour vasculature upon irradiation,
leading to complete and long-lasting cancer eradication. Furthermore, depletion experiments revealed that natural killer cells are
essential for the induction of long-lasting complete responses.
CONCLUSIONS: These results reinforce the concept that vascular shutdown can induce a curative avalanche of tumour cell death.
Immuno-photodynamic therapy may be particularly indicated for squamous cell carcinoma of the skin, which we show to be strongly
positive for markers of angiogenesis.
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Aggressive solid tumours (Folkman, 2006) and haematological
malignancies, such as lymphomas (Li et al, 2008; Sauer et al, 2009;
Schliemann et al, 2009a,b), myelomas (Atkins et al, 2008) and
nests of leukaemia blasts in the bone marrow (Padro et al, 2000),
depend on new blood vessels for their florid growth and
dissemination. As angiogenesis is a rare event in the healthy adult
(Carmeliet, 2003; Folkman, 2006), mainly confined to the female
reproductive cycle, therapeutic strategies have been devised that
aim at inhibiting the formation of new tumour blood vessels
(inhibition of angiogenesis) or at destroying the pre-formed
tumour neovasculature (vascular targeting).
Inhibition of key mediators of tumour angiogenesis has
culminated in the clinical application of Avastin, a humanised
monoclonal antibody binding soluble VEGF-A, thus stopping
interaction with its receptors (Ferrara et al, 2004; Hurwitz et al,
2004). However, although Avastin confers a survival benefit to
patients with colon, lung and kidney cancer when used in
combination with chemotherapy (Hurwitz et al, 2004), this agent
is rarely curative, as tumours often secrete multiple mediators of
angiogenesis that compensate for the loss of VEGF-A activity.
In principle, strategies aimed at selective destruction of existing
tumour blood vessels (rather than at inhibition of angiogenesis)
could have a more profound impact on the disease, causing an
avalanche of tumour cell death as a result of oxygen and nutrient
deprivation (Neri and Bicknell, 2005). Indeed, the antibody-based
targeted delivery of toxins or mild pro-coagulant factors to tumour
blood vessels can lead to tumour infarction in mouse models of
cancer. In some cases, complete tumour eradication was observed
(Thorpe et al, 1985; Huang et al, 1997; Nilsson et al, 2001).
Recently, tumour-targeting derivatives of a truncated form of
tissue factor have been moved to mechanistic clinical trials in
patients with cancer (Bieker et al, 2009).
Therapeutic strategies based on selective occlusion of tumour
vasculature are marked with an inherent paradox. Although, it is
clear that the collapse of tumour vasculature can lead to massive
tumour cell death, it is less obvious that all tumour cells (including
those at the periphery of the neoplastic lesion neighbouring on
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shealthy and well-oxygenated tissues) should die as a result of a
vascular insult. In fact, when solid tumours are treated with
combretastatins (small organic molecules that interfere with
tubulin polymerisation in endothelial cells causing a transient
occlusion of tumour blood vessels (Chaplin et al, 2006)), extensive
necrosis is observed only in the tumour core, whereas a rim
of neoplastic cells survives at the periphery of the lesion and leads
to progression of the disease (Chaplin et al, 2006; Heath and
Bicknell, 2009).
In the study presented here, to investigate whether and how
solid tumours can be completely eradicated solely as a result of a
vascular shutdown, we experimentally disrupted tumour blood
vessels by means of antibody–photosensitiser (PS) conjugates,
which selectively localise to the tumour neovasculature in vivo.W e
had previously reported that new blood vessels induced in the
cornea of rabbits could be completely ablated, following intrave-
nous injection of suitable antibody–PS conjugates and irradiation
with red light (Birchler et al, 1999). Moreover, we had
observed that similar conjugates can trigger rapid intraluminal
blood coagulation in small superficial tumours in mice (Fabbrini
et al, 2006).
Photodynamic therapy (PDT) is a localised, non-invasive
treatment modality for superficial malignancies that relies on the
combination of non-toxic PSs and visible light in the presence of
oxygen to generate cytotoxic reactive oxygen species. Photo-
dynamic therapy causes localised cell death directly by induction
of apoptosis and/or necrosis as well as indirectly by destruction of
tumour vasculature and delayed stimulation of an immune
response against the malignancy subjected to PDT (Castano
et al, 2006).
Photosensitisers are small organic molecules (typically
o1000kDa) that absorb light and that may display a toxic action
in their immediate surroundings either by generation of short-
lived reactive oxygen species (such as singlet oxygen) (Josefsen
and Boyle, 2008) or by localised heat generation (Chen et al, 1996).
To facilitate immuno-PDT studies, we developed porphyrin-based
PSs that absorb in the red light spectrum (approx. 630nm) and
that can be coupled to recombinant antibodies without compro-
mising their immunoreactivity and solubility. As vascular tumour
targeting agent, we used the human monoclonal antibody L19
specific to the alternatively spliced EDB domain of fibronectin, a
marker of angiogenesis (Zardi et al, 1987). Extra domain B has
identical sequence in mouse and man, which facilitates tumour
targeting studies in syngeneic animal models (Tarli et al, 1999;
Borsi et al, 2002; Berndorff et al, 2005). The small immune protein
(SIP) format was chosen for the antibody, which exclusively
localises to blood vessels within the tumour mass, as revealed by
microautoradiographic studies (Borsi et al, 2002). Several biodis-
tribution studies performed in tumour-bearing mice had pre-
viously indicated that the pharmacokinetic properties of
antibodies in SIP format are intermediate between the ones of
fast-clearing scFv fragments and those of IgG, and thus ideally
suited for in vivo vascular tumour targeting applications (Borsi
et al, 2002; Berndorff et al, 2005; Tijink et al, 2006). Indeed,
SIP(L19) labelled with the radionuclide iodine-131 has recently
shown its ability to preferentially localise to tumours in
clinical trials and to induce complete responses in patients with
radiosensitive lymphomas (Sauer et al, 2009). The L19 antibody
has also been fused with many cytokines (Carnemolla et al,
2002; Halin et al, 2002, 2003; Gafner et al, 2006; Kaspar et al,
2007) and two of these derivatives (L19-TNF (Halin et al, 2003)
and L19-IL2 (Carnemolla et al, 2002)) are currently being
studied in various phase I and phase II clinical trials in patients
with cancer.
The results presented in this study show that aggressive
tumours, implanted in the skin of nude mice, can be completely
eradicated as a result of vascular damage mediated by immuno-
PDT using SIP(L19)–PS conjugates. Interestingly, complete
tumour ablation required the presence of natural killer (NK) cells,
as only partial inhibition of tumour growth could be observed
following NK cell depletion with a monoclonal antibody specific to
asialo-GM1.
These findings reinforce the concept that the selective ablation
of tumour neovasculature can lead to long-lasting tumour
eradication and may be of clinical significance for the treatment
of squamous cell carcinoma (SCC).
Non-melanoma skin cancers such as basal cell carcinoma and
SCC, as well as in situ forms of SCC, represent the most frequent
type of cancer in the fair-skinned population. Their incidence is
increasing world wide, with immunocompromised patients being
particularly affected (Hofbauer et al, 2010). At present, SCC and
related malignancies are either removed by excision or treated with
non-surgical options such as radiotherapy and PDT.
MATERIALS AND METHODS
Chemistry
The PS used for conjugation to SIP(L19) was 5-[4-(succinimide-
N-oxycarbonyl)phenyl]-10,15,20-tris-(4-N-methylpyridimiumyl)-
porphyrin trichloride and was synthesised from commercially
available materials and is described in detail in the Supplementary
Online Materials.
Animals and cell lines
WI-38 VA-13 fibroblasts (ATCC number CCL-75.1), F9 murine
teratocarcinoma cells (ATCC number CRL-1720) and A431 human
epidermoid carcinoma cells (ATCC number CRL-1555) were
maintained in exponential growth in DMEM medium adjusted to
contain 4mML -glutamine, 4.5gl
 1 glucose, 10% foetal bovine
serum, 100Uml
 1 penicillin and 100mgml
 1 streptomycin (Gibco-
Invitrogen, Basel, Switzerland). Six- to eight-week-old female
Balb/c Nude CAnN.Cg-Foxn1nu/Crl mice were obtained from
Charles River Laboratories (Sulzfeld, Germany). All animal
experiments were performed under a project license granted by
the Veterina ¨ramt des Kantons Zu ¨rich (169/2008).
Antibodies
The cloning, expression and purification of SIP(L19), SIP(F8) and
SIP(F16) antibodies have been described previously (Borsi et al,
2002; Brack et al, 2006; Zuberbuhler et al, 2009). Briefly, SIP
cDNA was cloned into the pCDNA 3.1 vector (Invitrogen, Basel,
Switzerland). The construct was transfected in CHO-S cells,
and selected stable high-expressing clones were grown in Power-
CHO-Cd 2 medium (Lonza, Belgium) and used to produce the
antibodies, which were purified directly from the supernatant by
protein A affinity chromatography.
Preparation of photoimmunoconjugates
Small immune protein–PS (SIP–PS) conjugates were prepared as
follows: B20-fold molar excess of amine-reactive porphyrin (PS
10mgml
 1 in DMSO) was added to purified SIP antibody
(1mgml
 1, in PBS pH 7.4) and incubated for 4h at 301C, gently
shaking, avoiding light exposure. Small immune protein–PS
conjugates were then purified from free reagent over a PD-10
column (GE Healthcare, Glattburg, Switzerland) and dialyzed
overnight against PBS pH 7.4 at 41C.
Small immune protein–PS conjugates were analysed by SDS–
PAGE under reducing and non-reducing conditions using the
Invitrogen PAGE system following the manufacturer’s instructions.
The gels were first imaged under a Cy5 filter lamp and then stained
with Coomassie brilliant blue. The labelling ratio was estimated
spectroscopically by measuring the absorbance at 280nm for the
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sSIP (assuming that a 1mgml
 1 of SIP solution gives absorption of
1.4U at 280nm) and at 422nm for the PS (e¼159100M
 1cm
 1).
In addition, mass spectrometric analysis was used to assess the
labelling ratio. For MALDI-TOF/TOF MS analysis, the conjugates
were mixed with a sinapinic matrix (10mgml
 1 in 50% CAN and
0.05% TFA) at a 1:4 dilution and spotted onto a MALDI target
plate. Analysis of samples was performed on a freshly calibrated
AB4800 MALDI-TOF/TOF mass spectrometer (Applied Bio-
systems, Carlsbad, CA, USA). For data analysis, the Data Explorer
software (version 4.8) of Applied Biosystems was used. A Superdex
200 size-exclusion column (GE Healthcare) was used to analyse the
gel filtration profile of the antibodies before and after PS
conjugation under native conditions using fast protein liquid
chromatography (GE Healthcare).
Photokilling assay
For the in vitro photocytotoxicity assay WI-38 VA-13 fibroblasts
were used by seeding 30000 cells per well in a 96-well plate and
incubating overnight at 371Ci n5 %C O 2. The next day medium was
removed and cells were incubated with 50ml of SIP or SIP–
porphyrin conjugate in the appropriate dilutions (in PBS) for
1h at 371C. Cells were subsequently washed with PBS twice to
remove unbound antibodies, and cells were covered with 50mlo f
PBS. The cells were then irradiated using a KL 1500 electronic
tungsten halogen lamp (Zeiss, Jena, Germany) equipped with a
620/60 filter (Chroma, Bellows Falls, VT, USA) for a total light dose
of 60Jcm
 2. After light treatment, PBS was removed and 100mlo f
fresh medium were added. The cells were then incubated at 371C,
5% CO2 atmosphere over night. Controls include SIP–porphyrin
conjugate without irradiation, PBS only with irradiation, unmo-
dified SIP with irradiation and medium only without irradiation.
The following day, cell viability was measured using the Cell Titer
96Aqueous One Solution Cell Proliferation Assay (Promega,
Du ¨bendorf, Germany), following the manufacturer’s instructions.
The percentage of cell growth was calculated as a ratio of the
counts between treated cells over the relative control (cells treated
with SIP–porphyrin conjugate without light exposure).
Mouse model and PDT protocols
(A) F9 murine teratocarcinoma cells (3 10
6) were injected
subcutaneously into the flank of Balb/c nude mice. When tumours
were established and clearly palpable (B50mm
3), mice were
randomly distributed among the groups (4 animals per group) and
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Figure 1 Synthetic route to the photosensitiser 5-[4-(succinimide-N-oxycarbonyl)phenyl]-10,15,20-tris-(4-N-methylpyridimiumyl)porphyrin trichloride.
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Figure 2 Antibody–photosensitiser (PS) conjugates. (A) Schematic representation of an antibody in SIP format, consisting of a scFv fragment fused to an
e-CH4 domain of human IgE, which mediates non-covalent homodimerisation of the recombinant antibody molecule. A C-terminal cysteine residue
mediates the formation of covalent homodimers between the two subunits. Some of the primary amino groups of the antibody are covalently modified with
the PS described in Figure 1. (B) SDS–PAGE analysis (left panel, Coomassie blue staining; right panel, Cy5 fluorescence imaging) of SIP(L19)–PS: lanes
1 and 2, SIP(L19)–PS in non-reducing and reducing conditions, respectively; lanes 3–5, SIP(L19) standards of equal volume (0.8, 0.4 and 0.2mgml
 1,
respectively) in reducing conditions. (C) Size-exclusion chromatography profile of SIP(L19) (dashed line) and of SIP(L19)–PS conjugate (solid grey line).
(D) MALDI TOF/TOF mass spectra for SIP(L19) (dashed line) and SIP(L19)–PS conjugate (solid line).
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light dose of 60Jcm
 2) 24 and 48h after intravenous injection in
the tail lateral vein of 150mg of SIP(L19)–PS. In addition to
SIP(L19)–PS, control groups included mice receiving SIP(L19)–PS
in the absence of light, mice treated with an irrelevant antibody–
PS conjugate (SIP(F16)-PS) and mice treated with saline. For
depletion of NK cells (Habu et al, 1981), mice were treated with
0.3mg of anti-asialo GM1 antibody (Wako, Osaka, Japan) by
intraperitoneal injection every 5 days. Mice were anesthetised with
ketamine (40mgkg
 1)/xylazine (6mgkg
 1) before light irradia-
tion. Differences between different groups were compared using
Student’s t-test. (B) A431cells (3 10
6) were injected subcuta-
neously into the flank of Balb/c nude mice. When tumours were
established and clearly palpable (50–100mm
3), mice were
irradiated once with a laser (Ceralas PDT diode laser 635±3nm
cw 2W, total light dose of 60Jcm
 2) 24h after a single intravenous
injection in the tail lateral vein of 150mg of SIP(L19)–PS
conjugate. Mice were monitored daily and tumour growth was
measured three times per week with a digital caliper using the
following formula: volume¼length width width 0.5. Mice
were killed when the tumour reached a volume 42000mm
3.I n
addition, mice were photographed using a digital reflex camera
(Nikon D90).
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Figure 4 In vivo localisation of conjugates: ex vivo immunofluorescence analysis. (A) Binding of SIP(L19) and SIP(F16) to F9 tumour tissue evaluated by
fluorescent microscopic analysis of tumour sections after incubation with the biotinylated SIPs. (B) Fluorescent microscopic analysis of F9 tumour sections to
assess tumour targeting by SIP(L19)–PS (without or with previous depletion of NK cells), SIP(F16)–PS or saline 24h after injection. Dashed white line,
border between tumour (Tu) and normal (No) tissue. CD31, marker for endothelial cells. Scale bars, 100mm.
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Figure 3 Photocytotoxicity of SIP(L19)–PS (m) and SIP(L19) (’),
measured on WI-38 VA-13 fibroblasts using the MTS assay (obtained
values are the mean of at least three independent experiments±s.d.). The
curve is a fit of the data using the Hill equation.
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IHC/IHF, infiltration study) are reported in the Supplementary
Online Materials.
RESULTS
Synthesis of conjugatable PS derivatives
5-(4-Carboxyphenyl)-10,15,20-tri-(4-pyridyl)porphyrin was used
as starting material to introduce an activated ester that allows
the conjugation of this PS to amino residues on proteins.
To transform the carboxylic acid into the N-hydroxysuccinimide
ester, it was first converted to the corresponding acyl chloride by
reaction with thionyl chloride (Figure 1). The resulting acid
chloride was then reacted with N-hydroxysuccinimide. The final
step of the reaction sequence involved quaternisation with methyl
iodide to give the tricationic porphyrin. Iodide counter-ions were
exchanged for chlorides to increase water solubility as described
previously (Sutton et al, 2002).
Preparation and in vitro characterisation of antibody–PS
conjugates
Figure 2A presents the schematic structure of an antibody in SIP
format, where certain lysine residues have been covalently
modified with an amine-reactive PS moiety. Figure 2B shows the
results of SDS–PAGE analysis of SIP(L19) covalently modified
with PS, using Coomassie blue staining and fluorescence detection
methods. Complete formation of a disulphide-linked covalent
homodimer can be observed, which is disrupted when the sample
is run in reducing conditions. No free PS is detectable in the
sample. Figures 2C and D present size-exclusion chromatography
and mass spectrometric analysis of SIP(L19) before and after
conjugation with PS, indicating that the majority of the antibody
conjugate elutes with the retention expected for a covalent
homodimer, while exhibiting a Poisson distribution of molecular
masses in the fine MS analysis, reflecting a statistical labelling of
primary amino groups. At the average stoichiometric ratio of
monomeric SIP(L19)/PS¼1:3 (Figure 2D), the conjugate exhibited
490% retention of immunoreactivity, as revealed by affinity
chromatography on antigen resin.
Small immune protein(L19)–PS is a non-internalising antibody
conjugate. In line with previous observations (Birchler et al, 1999;
Fabbrini et al, 2006), this conjugate is able to kill cells when it
accumulates in their proximity given the presence of red light.
Figure 3 presents the results of a photokilling experiment
performed with WI38VA-transformed fibroblasts, which secrete
EDB-containing fibronectin (Carnemolla et al, 1996). When
irradiated with 150Jcm
 2 of red light, the target cells could be
completely killed in the presence of 100nM SIP(L19)–PS conjugate
(LD50¼3n M), whereas no detectable cell killing was observed
without irradiation.
In vivo characterisation of antibody–PS conjugates
Small immune protein(L19) exclusively stains blood vessels in
frozen sections of F9 tumours, as revealed by immunofluorescence
analysis. By contrast, SIP(F16) does not recognise any antigen in
the mouse (Brack et al, 2006), did not stain mouse F9 tumours in
our experiment (Figure 4A) and therefore was chosen as negative
control for therapy experiments. To confirm that SIP(L19)–PS
retains the vascular tumour targeting properties of the unmodified
antibody, we injected nude mice bearing F9 tumours with this
conjugate and detected its in vivo localisation by immunofluor-
escence analysis of tissue sections from animals killed 24h after
intravenous injection of the conjugate. Exclusive localisation to
tumours could be observed, with high selectivity for the tumour
neovasculature (Figure 4B).
Complete eradication of tumours by selective disruption
of tumour blood vessels
One molecule of homodimeric SIP(L19) was coupled to an average
of six PS molecules (Figure 2), resulting in a dose of PS
administered to the mice equal to 0.6mgkg
 1. This is an order
of magnitude less than doses typically required to cure tumours in
mice using PDT based on similar PSs (Korbelik and Dougherty,
1999).
To evaluate the in vivo therapeutic activity of SIP(L19)–PS, we
injected this conjugate in tumour-bearing mice (150mg per mouse)
and irradiated tumours with red light (two doses of 60Jcm
 2).
Mice treated with SIP(L19)–PS exhibited a strong anticancer
response, with three out of four complete eradications that were
long lasting (Supplementary Figure S1 and Figure 5A). In contrast,
mice receiving saline or SIP(F16)–PS displayed rapid tumour
growth despite irradiation. Similarly, mice treated with SIP(L19)–
PS in the absence of light did not exhibit any inhibition of tumour
growth (Figure 5A). The therapeutic action of SIP(L19)–PS was
due to the rapid photodynamic disruption of tumour blood
vessels, leading to extensive haemorrhage and oedema throughout
the tumour mass (Figure 6), as well as to widespread pyknosis and
karyorrhexis presaging massive tumour cell death.
We further tested SIP(L19)–PS in mice bearing A431 tumours as
a model of SCC of the skin. To mimic a clinical procedure for the
treatment of SCC patients, we injected the antibody–PS conjugate
in mice bearing subcutaneous A431 tumours in a single dose
(150mg), followed by 3min irradiation (60Jcm
 2) 24h later.
0
200
400
600
800
1000
1200
1400
1600
1800
02468 1 0 1 2 1 4
02468 1 0 1 2 9 0
15
CR 3/4
CR 4/4
T
u
m
o
u
r
 
v
o
l
u
m
e
 
(
m
m
3
)
0
200
400
600
800
1000
1200
1400
1600
T
u
m
o
u
r
 
v
o
l
u
m
e
 
(
m
m
3
)
Time (days)
Time (days) Injection:
Injection:
h:
h:
** *
A
B
Figure 5 Therapeutic activity of SIP(L19)–PS. (A) Nude mice bearing
subcutaneous F9 teratocarcinomas were injected intravenously with 150mg
of SIP(L19)–PS (E and K), SIP(F16)–PS (m) or saline (’) on days 0, 2,
4 and 6 of the treatment schedule, and tumours were irradiated daily with
60Jcm
 2 from days 1 to 8 (E, m and ’) or not irradiated at all (K);
*Po0.01 vs not irradiated, **Po0.01 vs saline. (B) Nude mice bearing
subcutaneous F9 teratocarcinomas were injected with 150mg of SIP(L19)–
PS (E and K) or saline (’) on days 0, 2 and 4, and tumours were
irradiated daily with 60Jcm
 2 from days 1 to 6. Mice in one of the groups
receiving PS conjugate were depleted of NK cells by injections of 0.3mg of
an anti-asialo-GM1 antibody every 5 days during therapy, starting at day  1
of the therapy regimen (K). CR, complete response. hn, irradiation.
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sAlthough tumours in saline-injected mice were not affected by
irradiation, A431 lesions in mice receiving SIP(L19)–PS were
rapidly converted into black scabs (Figure 7A) as a result of
selective disruption of the tumour vasculature. The lesions healed
completely and with excellent cosmetic outcome within 2 weeks of
their immuno-photodynamic ablation (Figure 7A) and did not
grow back for the subsequent 100 days after treatment.
Essential role of NK cells in complete tumour eradication
The complete tumour eradication observed as a result of selective
vascular damage is counter-intuitive, as one would expect tumour
cells at the periphery (i.e., adjacent to normal, well-perfused tissue)
to survive and re-grow (Chaplin et al, 2006; Heath and Bicknell,
2009). To investigate whether NK cells could contribute to tumour
eradication following vascular disruption, immuno-PDT with
SIP(L19)–PS was performed in the presence or absence of NK
cell depletion (Figure 5B). As in the previous experiment, complete
tumour eradication (four out of four mice) was observed in
animals treated with SIP(L19)–PS. By contrast, tumours continued
to grow in mice that had received saline treatment. Interestingly,
removal of NK cells (mediated by an anti-asialo GM1 antibody)
before and during immuno-photodynamic treatment with
SIP(L19)–PS abrogated the therapeutic effect, resulting only in
transient tumour growth retardation followed by progression
(Figure 5B).
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Figure 6 Effect of PDT with SIP(L19) –PS on tumour histology. Sections of F9 tumours excised 1h after irradiation, stained with haematoxylin/eosin,
photographed at  2.5 (B),  5( A, left panel),  10 (A, middle panel) and  40 (A, right panel) magnification.
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sNatural killer cells efficiently infiltrated tumours within 6h
after immuno-PDT treatment (Figure 8). In contrast, tumours of
mice injected with saline or depleted of NK cells before therapy
were virtually devoid of NK cells. The levels of macrophages were
similar in tumours of mice treated with SIP(L19)–PS or saline.
However, infiltration of tumours by macrophages increased
substantially in immuno-PDT experiments where NK cells were
depleted before therapy (Figure 8), possibly attempting to
compensate for the missing population of NK cells.
Immunofluorescence analysis of human specimens of SCC
To investigate whether immuno-PDT strategies based on vascular
targeting antibodies could be used for the ablation of skin lesions
of SCC, we first performed an analysis by immunofluorescence
samples of human SCCs and normal skin, using in addition to L19,
the F8 and F16 human antibodies, specific to the alternatively
spliced EDA and the A1 domain of tenascin-C, respectively
(Schliemann et al, 2009b). Like the EDB, these extra-domains are
virtually undetectable in normal adult tissues (Neri and Bicknell,
2005), but are often abundantly expressed around tumour blood
vessels in primary tumours and in metastases (Neri and Bicknell,
2005). Figure 7B shows the immunofluorescence analysis of
SCC lesions obtained from a small cohort of patients, in which a
selective staining of vascular and stromal structures could be
observed for the L19, F8 and F16 antibodies. Furthermore,
these antibodies are able to strongly stain frozen sections of an
SCC-like mouse tumour based on the A431 epidermoid carcinoma
cells, xenografted subcutaneously in nude mice (Supplementary
Figure S2).
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sDISCUSSION
In this article, we have shown that an antibody–PS conjugate
specific to the alternatively spliced EDB domain of fibronectin, a
marker of angiogenesis, has the ability to localise selectively
around tumour blood vessels in vivo. This allows selectively
damaging the tumour vasculature by irradiation with red light,
leading to massive tumour cell death and to lasting cures.
Depletion experiments indicated that the action of NK cells is
essential for the induction of complete cancer eradication, killing
cells neighbouring on normal tissue at the periphery of the
tumour.
In the past, selective damaging of tumour neovasculature has
been studied with antibody–toxin and antibody–tissue factor
conjugates (Thorpe et al, 1985; Ran et al, 1998), as well as with
pharmacological agents (e.g., combretastatins (Hinnen and Eskens,
2007), ASA404 (Head and Jameson, 2010)) capable of preferential
interaction with tumour endothelial cells (Chaplin et al, 2006;
Martinelli et al, 2007; Siemann et al, 2009). Indeed, this latter class
of vasculature-disrupting agents has been investigated in clinical
trials in patients with cancer, revealing that combretastatin-A4 can
lead to enhanced tumour responses when combined with radio-
therapy or anticancer drugs (i.e., carboplatin, paclitaxel) (Siemann
et al, 2009) and that the flavonoid ASA-404 potentiates the action
of taxane-based chemotherapeutic regimens in patients with
non-small-cell lung cancer (Head and Jameson, 2010).
In principle, vasculature-disrupting agents like combretastatins,
while having a clear impact on vascular structures of tumours
(Heath and Bicknell, 2009), could act in part also on other cells of
tumours and stroma (Heath and Bicknell, 2009). Furthermore,
when used as single agents, combretastatins induce only a
transient shutdown of tumour blood vessels and do not cure
cancer (Heath and Bicknell, 2009). By contrast, the use of
vascular targeting antibody derivatives (Neri and Bicknell, 2005)
allows to confirm experimentally the selective localisation of the
therapeutic agent on the tumour neovasculature by a variety of
experimental techniques, including ex vivo fluorescence micro-
scopy (Figure 4B) or microautoradiographic analysis (Borsi et al,
2002; Villa et al, 2008). The use of PSs as bioactive payloads
ensures that therapy starts precisely when tumours are
irradiated, that is, at a point in time when the concentration of
antibody conjugate on non-vascular tumour cells and in
normal tissue is negligibly low. Indeed, anti-EDB antibodies
localise to the subendothelial extracellular matrix around
tumour blood vessels (Borsi et al, 2002; Niesner et al, 2002), and
antibody-delivered PSs mediate the disruption of adjacent
tumour vasculature by acting on proximal endothelial cells
through diffusible reactive oxygen species (Josefsen and Boyle,
2008) or through local generation of heat (Chen et al, 1996;
Yu et al, 2010).
At present, approved clinical applications of PDT are mainly
limited to localised skin cancers (such as basal cell carcinoma and
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Figure 8 Lymphocyte infiltration of tumours following PDT with SIP(L19)–PS. Microscopic immunofluorescence analysis of F9 tumour sections revealing
the degree of infiltration by NK cells and macrophages, respectively, 6h after PDT based on saline or SIP(L19)–PS without or with previous depletion of
NK cells. Magnification:  10.
NKs required for tumour ablation by vascular damage
A Palumbo et al
1113
British Journal of Cancer (2011) 104(7), 1106–1115 & 2011 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sin situ SCC), actinic keratosis, head and neck carcinomas and the
premalignant condition Barrett’s oesophagus. Light penetration of
tissues reaches a maximum of only several millimetres at
wavelengths around 750–800nm (Wan et al, 1981), thus
limiting practical applications to superficial cancer or endoscopi-
cally accessible lesions. However, the additional selectivity
associated with the antibody-based delivery of PSs promises to
extend the applicability of this methodology, while limiting side
effects.
Our results show that human SCC of the skin can be selectively
targeted by SIPs and that human skin tumours implanted in nude
mice can be ablated in a curative manner by one single dose of
immuno-PDT based on a vascular targeting antibody–PS con-
jugate. Complete responses were achieved at a dramatically
reduced dose of PS compared with conventional (non-targeted)
PDT regimens. These findings suggest that the therapeutic efficacy
of PDT in the clinical treatment of human skin cancers may be
greatly enhanced by the selective delivery of PSs conjugated to
vascular tumour-targeting antibodies. At the same time, we
envisage a significant reduction of curative PS doses and of side
effects in such targeted immuno-PDT regimens.
Clinical trials are now needed to elucidate whether the
promising results obtained with SIP(L19)–PS in the A431 tumour
model are confirmed in patients with cutaneous SCC or other EDB-
positive skin lesions. If so, then antibody–PS conjugates such as
SIP(L19)–PS may greatly extend the applicability of immuno-PDT
in the clinic, sparing many skin cancer patients the more invasive
treatment modalities of surgery and radiotherapy.
Independently of any practical application of immuno-PDT
(Kuimova et al, 2007), the data presented in this study
unequivocally confirm that a selective damage of the tumour
neovasculature leads to an avalanche of tumour cell deaths and is
sufficient for complete and long-lasting eradication of tumours
that are not cured by conventional chemotherapy (Ebbinghaus
et al, 2005).
Natural killer cells play a crucial role in the mechanism of action
of anticancer therapeutic antibodies (e.g., rituximab, trastuzu-
mab), engaging the Fc portion of the antibody with Fc-g receptor
3a (FCGR3A, CD16), leading to degranulation (Cartron et al, 2002).
High-affinity variants in the FCGR3A polymorphism have been
associated with better response to therapeutic antibodies (Cartron
et al, 2002). Furthermore, protein engineering strategies that
increase the binding affinity of antibodies to the cognate Fc
receptor may dramatically potentiate the anticancer activity of
therapeutic antibodies (Umana et al, 1999; Presta et al, 2002;
Nimmerjahn and Ravetch, 2005). The activity of NK cells can be
boosted by the targeted delivery of certain pro-inflammatory
cytokines by means of vascular targeting antibodies (Carnemolla
et al, 2002; Halin et al, 2002, 2003; Borsi et al, 2003; Schliemann
et al, 2009a). Our discovery of the important role played by NK
cells in the eradication of cancer following selective disruption of
tumour blood vessels may provide a strong rationale for the
combination of vascular disrupting agents with immunostimula-
tory drugs (e.g., immunocytokines) in cancer therapy.
ACKNOWLEDGEMENTS
This work was supported by the Swiss National Science Founda-
tion (Grant number 3100A0-105919/1); ETH Zurich; the European
Union projects IMMUNO-PDT (Grant number LSHC-CT-2006-
037489) and ADAMANT (Grant number HEALT-F2-2008-201342);
the Swiss Bridge Foundation; the Stammbach Foundation; and the
Swiss Cancer League (Robert Wenner Award to DN). AP is
member of the Cancer Biology PhD program of the Life Science
Zurich Graduate School.
Supplementary Information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc)
REFERENCES
Atkins MB, Sosman JA, Agarwala S, Logan T, Clark JI, Ernstoff MS,
Lawson D, Dutcher JP, Weiss G, Curti B, Margolin KA (2008)
Temozolomide, thalidomide, and whole brain radiation therapy for
patients with brain metastasis from metastatic melanoma: a phase II
Cytokine Working Group study. Cancer 113(8): 2139–2145
Berndorff D, Borkowski S, Sieger S, Rother A, Friebe M, Viti F, Hilger CS,
Cyr JE, Dinkelborg LM (2005) Radioimmunotherapy of solid tumors by
targeting extra domain B fibronectin: identification of the best-suited
radioimmunoconjugate. Clin Cancer Res 11(19, Part 2): 7053s–7063s
Bieker R, Kessler T, Schwoppe C, Padro T, Persigehl T, Bremer C,
Dreischaluck J, Kolkmeyer A, Heindel W, Mesters RM, Berdel WE (2009)
Infarction of tumor vessels by NGR-peptide-directed targeting of tissue
factor: experimental results and first-in-man experience. Blood 113(20):
5019–5027
Birchler M, Neri G, Tarli L, Halin C, Viti F, Neri D (1999) Infrared
photodetection for the in vivo localisation of phage-derived antibodies
directed against angiogenic markers. J Immunol Methods 231(1–2):
239–248
Borsi L, Balza E, Bestagno M, Castellani P, Carnemolla B, Biro A, Leprini A,
Sepulveda J, Burrone O, Neri D, Zardi L (2002) Selective targeting of
tumoral vasculature: comparison of different formats of an antibody
(L19) to the ED-B domain of fibronectin. Int J Cancer 102(1): 75–85
Borsi L, Balza E, Carnemolla B, Sassi F, Castellani P, Berndt A, Kosmehl H,
Biro A, Siri A, Orecchia P, Grassi J, Neri D, Zardi L (2003) Selective
targeted delivery of TNFalpha to tumor blood vessels. Blood 102(13):
4384–4392
Brack SS, Silacci M, Birchler M, Neri D (2006) Tumor-targeting properties
of novel antibodies specific to the large isoform of tenascin-C. Clin
Cancer Res 12(10): 3200–3208
Carmeliet P (2003) Angiogenesis in health and disease. Nat Med 9(6):
653–660
Carnemolla B, Borsi L, Balza E, Castellani P, Meazza R, Berndt A, Ferrini S,
Kosmehl H, Neri D, Zardi L (2002) Enhancement of the antitumor
properties of interleukin-2 by its targeted delivery to the tumor blood
vessel extracellular matrix. Blood 99(5): 1659–1665
Carnemolla B, Neri D, Castellani P, Leprini A, Neri G, Pini A, Winter G,
Zardi L (1996) Phage antibodies with pan-species recognition of the
oncofoetal angiogenesis marker fibronectin ED-B domain. Int J Cancer
68(3): 397–405
Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P,
Watier H (2002) Therapeutic activity of humanized anti-CD20 mono-
clonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa
gene. Blood 99(3): 754–758
Castano AP, Mroz P, Hamblin MR (2006) Photodynamic therapy and anti-
tumour immunity. Nat Rev Cancer 6(7): 535–545
Chaplin DJ, Horsman MR, Siemann DW (2006) Current development status
of small-molecule vascular disrupting agents. Curr Opin Invest Drugs
7(6): 522–528
Chen WR, Adams RL, Higgins AK, Bartels KE, Nordquist RE (1996)
Photothermal effects on murine mammary tumors using indocyanine
green and an 808-nm diode laser: an in vivo efficacy study. Cancer Lett
98(2): 169–173
Ebbinghaus C, Ronca R, Kaspar M, Grabulovski D, Berndt A, Kosmehl H,
Zardi L, Neri D (2005) Engineered vascular-targeting antibody-interferon-
gamma fusion protein for cancer therapy. I n tJC a n c e r116(2): 304–313
Fabbrini M, Trachsel E, Soldani P, Bindi S, Alessi P, Bracci L, Kosmehl H,
Zardi L, Neri D, Neri P (2006) Selective occlusion of tumor blood vessels
by targeted delivery of an antibody-photosensitizer conjugate. Int J
Cancer 118(7): 1805–1813
Ferrara N, Hillan KJ, Gerber HP, Novotny W (2004) Discovery and
development of bevacizumab, an anti-VEGF antibody for treating cancer.
Nat Rev Drug Discov 3(5): 391–400
NKs required for tumour ablation by vascular damage
A Palumbo et al
1114
British Journal of Cancer (2011) 104(7), 1106–1115 & 2011 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sFolkman J (2006) Angiogenesis. Annu Rev Med 57: 1–18
Gafner V, Trachsel E, Neri D (2006) An engineered antibody-interleukin-12
fusion protein with enhanced tumor vascular targeting properties. Int J
Cancer 119(9): 2205–2212
Habu S, Fukui H, Shimamura K, Kasai M, Nagai Y, Okumura K, Tamaoki N
(1981) In vivo effects of anti-asialo GM1. I. Reduction of NK activity and
enhancement of transplanted tumor growth in nude mice. J Immunol
127(1): 34–38
Halin C, Gafner V, Villani ME, Borsi L, Berndt A, Kosmehl H, Zardi L,
Neri D (2003) Synergistic therapeutic effects of a tumor targeting
antibody fragment, fused to interleukin 12 and to tumor necrosis factor
alpha. Cancer Res 63(12): 3202–3210
Halin C, Rondini S, Nilsson F, Berndt A, Kosmehl H, Zardi L, Neri D (2002)
Enhancement of the antitumor activity of interleukin-12 by targeted
delivery to neovasculature. Nat Biotechnol 20(3): 264–269
Head M, Jameson MB (2010) The development of the tumor vascular-
disrupting agent ASA404 (vadimezan, DMXAA): current status and
future opportunities. Expert Opin Invest Drugs 19(2): 295–304
Heath VL, Bicknell R (2009) Anticancer strategies involving the vascu-
lature. Nat Rev Clin Oncol 6(7): 395–404
Hinnen P, Eskens FA (2007) Vascular disrupting agents in clinical
development. Br J Cancer 96(8): 1159–1165
Hofbauer GF, Bouwes Bavinck JN, Euvrard S (2010) Organ transplantation
and skin cancer: basic problems and new perspectives. Exp Dermatol
19(6): 473–482
Huang X, Molema G, King S, Watkins L, Edgington TS, Thorpe PE (1997)
Tumor infarction in mice by antibody-directed targeting of tissue factor
to tumor vasculature. Science 275(5299): 547–550
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J,
Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G,
Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan,
fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J
Med 350(23): 2335–2342
Josefsen LB, Boyle RW (2008) Photodynamic therapy and the development
of metal-based photosensitisers. Met Based Drugs 2008: 276109
Kaspar M, Trachsel E, Neri D (2007) The antibody-mediated targeted
delivery of interleukin-15 and GM-CSF to the tumor neovasculature
inhibits tumor growth and metastasis. Cancer Res 67(10): 4940–4948
Korbelik M, Dougherty GJ (1999) Photodynamic therapy-mediated
immune response against subcutaneous mouse tumors. Cancer Res
59(8): 1941–1946
Kuimova MK, Bhatti M, Deonarain M, Yahioglu G, Levitt JA, Stamati I,
Suhling K, Phillips D (2007) Fluorescence characterisation of multiply-
loaded anti-HER2 single chain Fv-photosensitizer conjugates suitable for
photodynamic therapy. Photochem Photobiol Sci 6(9): 933–939
Li WW, Hutnik M, Gehr G (2008) Antiangiogenesis in haematological
malignancies. Br J Haematol 143(5): 622–631
Martinelli M, Bonezzi K, Riccardi E, Kuhn E, Frapolli R, Zucchetti M,
Ryan AJ, Taraboletti G, Giavazzi R (2007) Sequence dependent
antitumour efficacy of the vascular disrupting agent ZD6126 in
combination with paclitaxel. Br J Cancer 97(7): 888–894
Neri D, Bicknell R (2005) Tumour vascular targeting. Nat Rev Cancer 5(6):
436–446
Niesner U, Halin C, Lozzi L, Gunthert M, Neri P, Wunderli-Allenspach H,
Zardi L, Neri D (2002) Quantitation of the tumor-targeting properties of
antibody fragments conjugated to cell-permeating HIV-1 TAT peptides.
Bioconjug Chem 13(4): 729–736
N i l s s o nF ,K o s m e h lH ,Z a r d iL ,N e r iD( 2 0 01) Targeted delivery of tissue factor
t ot h eE D - Bd o m a i no ff i b r o n e c t i n ,am a r k e ro fa n g i o g e n e s i s ,m e d i a t e st h e
infarction of solid tumors in mice. Cancer Res 61(2): 711–716
Nimmerjahn F, Ravetch JV (2005) Divergent immunoglobulin g
subclass activity through selective Fc receptor binding. Science
310(5753): 1510–1512
Padro T, Ruiz S, Bieker R, Burger H, Steins M, Kienast J, Buchner T, Berdel
WE, Mesters RM (2000) Increased angiogenesis in the bone marrow of
patients with acute myeloid leukemia. Blood 95(8): 2637–2644
Presta LG, Shields RL, Namenuk AK, Hong K, Meng YG (2002) Engineering
therapeutic antibodies for improved function. Biochem Soc Trans 30(4):
487–490
Ran S, Gao B, Duffy S, Watkins L, Rote N, Thorpe PE (1998) Infarction of
solid Hodgkin’s tumors in mice by antibody-directed targeting of tissue
factor to tumor vasculature. Cancer Res 58(20): 4646–4653
Sauer S, Erba PA, Petrini M, Menrad A, Giovannoni L, Grana C, Hirsch B,
Zardi L, Paganelli G, Mariani G, Neri D, Durkop H, Menssen HD (2009)
Expression of the oncofetal ED-B-containing fibronectin isoform in
hematologic tumors enables ED-B-targeted
131I-L19SIP radioimmu-
notherapy in Hodgkin lymphoma patients. Blood 113(10): 2265–2274
Schliemann C, Palumbo A, Zuberbuhler K, Villa A, Kaspar M, Trachsel E,
Klapper W, Menssen HD, Neri D (2009a) Complete eradication of human
B-cell lymphoma xenografts using rituximab in combination with the
immunocytokine L19-IL2. Blood 113(10): 2275–2283
Schliemann C, Wiedmer A, Pedretti M, Szczepanowski M, Klapper W,
Neri D (2009b) Three clinical-stage tumor targeting antibodies reveal
differential expression of oncofetal fibronectin and tenascin-C isoforms
in human lymphoma. Leuk Res 33(12): 1718–1722
Siemann DW, Chaplin DJ, Walicke PA (2009) A review and update of the
current status of the vasculature-disabling agent combretastatin-A4
phosphate (CA4P). Expert Opin Invest Drugs 18(2): 189–197
Sutton JM, Clarke OJ, Fernandez N, Boyle RW (2002) Porphyrin, chlorin,
and bacteriochlorin isothiocyanates: useful reagents for the synthesis of
photoactive bioconjugates. Bioconjug Chem 13(2): 249–263
Tarli L, Balza E, Viti F, Borsi L, Castellani P, Berndorff D, Dinkelborg L,
Neri D, Zardi L (1999) A high-affinity human antibody that targets
tumoral blood vessels. Blood 94(1): 192–198
Thorpe PE, Brown AN, Bremner Jr JA, Foxwell BM, Stirpe F (1985) An
immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a
ribosome-inactivating protein from Saponaria officinalis: potent anti-
tumor effects in vitro and in vivo. J Natl Cancer Inst 75(1): 151–159
Tijink BM, Neri D, Leemans CR, Budde M, Dinkelborg LM, Stigter-van
Walsum M, Zardi L, van Dongen GA (2006) Radioimmunotherapy of
head and neck cancer xenografts using
131I-labeled antibody L19-SIP for
selective targeting of tumor vasculature. J Nucl Med 47(7): 1127–1135
Umana P, Jean-Mairet J, Moudry R, Amstutz H, Bailey JE (1999)
Engineered glycoforms of an antineuroblastoma IgG1 with optimized
antibody-dependent cellular cytotoxic activity. Nat Biotechnol 17(2):
176–180
Villa A, Trachsel E, Kaspar M, Schliemann C, Sommavilla R, Rybak JN,
Rosli C, Borsi L, Neri D (2008) A high-affinity human monoclonal
antibody specific to the alternatively spliced EDA domain of fibronectin
efficiently targets tumor neo-vasculature in vivo. Int J Cancer 122(11):
2405–2413
Wan S, Parrish JA, Anderson RR, Madden M (1981) Transmittance of
nonionizing radiation in human tissues. Photochem Photobiol 34(6):
679–681
Yu J, Javier D, Yaseen MA, Nitin N, Richards-Kortum R, Anvari B, Wong
MS (2010) Self-assembly synthesis, tumor cell targeting, and photo-
thermal capabilities of antibody-coated indocyanine green nanocapsules.
J Am Chem Soc 132(6): 1929–1938
Zardi L, Carnemolla B, Siri A, Petersen TE, Paolella G, Sebastio G, Baralle
FE (1987) Transformed human cells produce a new fibronectin isoform
by preferential alternative splicing of a previously unobserved exon.
EMBO J 6(8): 2337–2342
Zuberbuhler K, Palumbo A, Bacci C, Giovannoni L, Sommavilla R,
Kaspar M, Trachsel E, Neri D (2009) A general method for the selection
of high-level scFv and IgG antibody expression by stably transfected
mammalian cells. Protein Eng Des Sel 22(3): 169–174
NKs required for tumour ablation by vascular damage
A Palumbo et al
1115
British Journal of Cancer (2011) 104(7), 1106–1115 & 2011 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
s